Long-term Prognosis of Paroxysmal Atrial Fibrillation and Predictors for Progression to Persistent or Chronic Atrial Fibrillation in the Korean Population

Sung Il Im,1 Kwang Jin Chun,2 Seung-Jung Park,2 Kyoung-Min Park,2 June Soo Kim,2 and Young Keun On1

1Division of Cardiology, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan; 2Division of Cardiology, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Received: 10 October 2014 Accepted: 17 February 2015

Address for Correspondence:
Young Keun On, MD
Division of Cardiology, Heart Vascular and Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Inwon-ro Gangnam-gu, Seoul 135-710, Korea
Tel: +82.2-3410-3420, Fax: +82.2-3410-3849
E-mail: ykon@samsung.com

INTRODUCTION

Atrial fibrillation (AF) is the most common clinically significant arrhythmia in clinical practice. AF is associated with increased morbidity and mortality that primarily occur as a result of complications, such as thromboembolic events and heart failure (1, 2).

In clinical practice, one should distinguish between the AF clinical types: paroxysmal AF (PAF): episodes of the arrhythmia that terminate spontaneously; persistent AF (PeAF): episodes that are sustained 7 days or more and are not self-terminating; permanent AF: ongoing long-term episodes (3), which will affect the individual treatment strategy for each patient (4).

AF usually starts as PAF and transforms into PeAF (5). The mechanism of PAF consists of initiating factors. The role of the maintenance factors is less important, but becomes more important in association with progression of AF to PeAF or permanent AF (6, 7). This seems particularly to be a concern in patients with PeAF or permanent AF, whose higher incidence of events from cardiac and non-cardiac origins can affect long-term outcomes (8).

Little is known about the long-term prognosis of or predictors for the different clinical types of atrial fibrillation (AF) in Korean populations. The aim of this study was to validate a risk stratification to assess the probability of AF progression from paroxysmal AF (PAF) to persistent AF (PeAF) or permanent AF. A total of 434 patients with PAF were consecutively enrolled (mean age; 71.7 ± 10.7 yr, 60.6% male). PeAF was defined as episodes that are sustained > 7 days and not self-terminating, while permanent AF was defined as an ongoing long-term episode. Atrial arrhythmia during follow-up was defined as atrial premature complex, atrial tachycardia, and atrial flutter. During a mean follow-up of 72.7 ± 58.3 months, 168 patients (38.7%) with PAF progressed to PeAF or permanent AF. The mean annual AF progression was 10.7% per year. In univariate analysis, age at diagnosis, body mass index, atrial arrhythmia during follow-up, left ventricular ejection fraction, concentric left ventricular hypertrophy, left atrial diameter (LAD), and severe mitral regurgitation (MR) were significantly associated with AF progression. In multivariate analysis, age at diagnosis (P = 0.009), atrial arrhythmia during follow-up (P = 0.015), LAD (P = 0.002) and MR grade (P = 0.026) were independent risk factors for AF progression.

Patients with younger age at diagnosis, atrial arrhythmia during follow-up, larger left atrial chamber size, and severe MR grade are more likely to progress to PeAF or permanent AF, suggesting more intensive medical therapy with close clinical follow-up would be required in those patients.

Keywords: Paroxysmal Atrial Fibrillation; Progression; Korean Populations
MATERIALS AND METHODS

Study populations
In our study, total 2,413 patients with AF were reviewed for 18 yr. The patients were excluded if they had one of the following conditions; including a recent history of acute infection or inflammatory disease, age > 80 yr old, a history of cardiomyopathy, or valvular (defined as ≥ moderate mitral regurgitation, aortic regurgitation, aortic stenosis or a presence of prosthetic heart valve or history of repair) or congenital heart disease, hepatic or renal disease, an acute cardiovascular or cerebrovascular event within the preceding 3 months, any major trauma or surgery within the preceding 3 months, hyperthyroidism, uncontrolled hypertension, malignancy, connective tissue disease, or any acute or chronic inflammatory disease.

Finally, a total 434 patients with PAF were enrolled and we retrospectively analyzed those 434 non-valvular PAF patients (mean age: 71.7 ± 10.7 yr, 60.6% male) consecutively. Patients with a history of PAF documented by a standard electrocardiogram (ECG) or Holter-ECG were enrolled. The flow chart is shown in Fig. 1. The baseline characteristics of the patients are present- ed in Table 1.

Data collection
After ECG and chest radiograph, cardiovascular status was evaluated for each patient using echocardiography, an exercise test, 24-hr Holter recordings, and blood laboratory data from the initial visit, as determined by the attending physicians. From the database, the following information was collected: 1) patient data, including sex, age, height, and weight; 2) cardiovascular risk factors, including hypertension (use of antihypertensive agents, systolic blood pressure ≥ 140 mmHg), or diastolic blood pressure 90 mmHg on admission) and diabetes mellitus (use of oral hypoglycemic agents or insulin, or glycosylated hemoglobin ≥ 6.5%); 3) cardiovascular disease status, including

Table 1. Baseline clinical characteristics in patients with PAF depending on the progression to persistent or permanent AF

| Parameters             | PAF or SR group (n = 253) | Progression to PeAF or permanent AF group (n = 168) | P value |
|------------------------|---------------------------|---------------------------------------------------|--------|
| Age (yr)               | 63.8 ± 11.2               | 61.2 ± 10.7                                       | 0.019  |
| Gender (Male, %)       | 152 (60.1)                | 104 (61.9)                                        | 0.760  |
| DM (%)                 | 47 (18.6)                 | 34 (20.2)                                         | 0.706  |
| HTN (%)                | 147 (58.1)                | 95 (56.5)                                         | 0.764  |
| CHF (%)                | 8 (3.2)                   | 6 (3.6)                                           | 0.790  |
| Hyperlipidemia (%)     | 51 (20.2)                 | 30 (17.9)                                         | 0.614  |
| BMI (%)                | 24.6 ± 3.0                | 25.2 ± 2.8                                        | 0.042  |
| CVA (%)                | 30 (11.9)                 | 21 (12.5)                                         | 0.879  |
| Renal failure (%)      | 4 (1.6)                   | 3 (1.8)                                           | 0.207  |
| CHADS2                 | 1.3 ± 1.2                 | 1.2 ± 1.1                                         | 0.372  |
| CHA2DS-Vasc            | 2.0 ± 1.4                 | 1.8 ± 1.4                                         | 0.151  |
| HATCH score            | 1.1 ± 1.0                 | 1.0 ± 1.0                                         | 0.537  |
| CAD (%)                | 28 (11.1)                 | 20 (11.9)                                         | 0.876  |
| PAD (%)                | 13 (5.1)                  | 5 (3.0)                                           | 0.333  |
| Medications            |                           |                                                   |        |
| Anti-arrhythmics (%)   |                           |                                                   |        |
| Amiodarone (%)         | 13 (5.1)                  | 21 (12.5)                                         | 0.010  |
| Dronedarone (%)        | 1 (0.4)                   | 0 (0)                                             | 1.000  |
| Propafenone (%)        | 41 (16.2)                 | 17 (10.1)                                         | 0.084  |
| Flecainide (%)         | 7 (2.8)                   | 1 (0.6)                                           | 0.153  |
| Sotalol (%)            | 5 (2.0)                   | 5 (3.0)                                           | 0.529  |
| Beta-blocker (%)       | 67 (26.5)                 | 47 (28.0)                                         | 0.738  |
| Calcium channel blocker (%) | 86 (34.0)  | 61 (36.3)                                         | 0.676  |
| ARB (%)                | 58 (22.9)                 | 32 (19.0)                                         | 0.396  |
| ACE (%)                | 16 (6.3)                  | 15 (8.9)                                          | 0.344  |
| Statins (%)            | 42 (16.6)                 | 21 (12.5)                                         | 0.267  |
| Aspirin (%)            | 137 (54.2)                | 90 (53.6)                                         | 0.921  |
| Clopidogrel (%)        | 11 (4.3)                  | 10 (6.0)                                          | 0.498  |
| Warfarin (%)           | 56 (22.1)                 | 39 (23.3)                                         | 0.813  |
| Rivaroxaban (%)        | 0 (0)                     | 0 (0)                                             | 1.000  |
| Dabigatran (%)         | 1 (0.4)                   | 0 (0)                                             | 1.000  |

Values are mean ± SD (range). PAF indicates paroxysmal atrial fibrillation; PeAF, persistent atrial fibrillation; AF, atrial fibrillation; SR, sinus rhythm; DM, diabetes mellitus; HTN, hypertension; CHF, congestive heart failure; BMI, body mass index; CVA, cerebrovascular accident; CHADS score, 1 point for congestive heart failure, hypertension, age ≥ 75 yr, diabetes mellitus, and 2 points for history of stroke or transient ischemic attack; CHA2DS-Vasc score, 1 point for congestive heart failure, hypertension, diabetes mellitus, vascular disease (previous myocardial infarction, complex aortic plaque, and peripheral artery disease [PAD]), age ≥ 65-74 yr and 2 points for history of stroke or transient ischemic attack, age ≥ 75 yr; HATCH score, 1 point for hyper tension, age ≥ 75 yr, chronic obstructive pulmonary disease and 2 points for transient ischemic attack or stroke, heart failure (2 points); CAD, coronary artery disease; PAD, peripheral artery disease; CMP, cardiomyopathy; DCMP, dilated cardiomyopathy; HCMP, hypertrophic cardiomyopathy; ICMP, ischemic cardiomyopathy; SCMP, stress cardiomyopathy; ARB, angiotensin II receptor blocker; ACEI, angiotensin converting enzyme inhibitor.

Fig. 1. Patient selection procedure.
structural heart disease, congestive heart failure, or a history of a disabling cerebral infarction or TIA; and 4) use of medication. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters.

Definitions of atrial fibrillation, atrial arrhythmia, and clinical events
In the present study, paroxysmal AF at the initial visit was defined as sinus rhythm on ECG and previous diagnosis of paroxysmal AF by referring physicians. Patients whose AF was estimated to continue for ≥ 7 days after the initial visit were considered to have persistent AF originally and were excluded from the analysis. Permanent AF was defined as an ongoing long-term episode. Asymptomatic AF was defined as AF documented on 12-lead ECG during a visit, in the absence of any new symptoms such as palpitations, tachycardia, fatigue, malaise, shortness of breath on exertion, dyspnea, chest pain, syncope, or pre-syncope related to AF or other illnesses. During the follow-up period, the onset of persistent AF was defined as the first time in which all ECGs indicated AF after ≥ 3 consecutive ECGs at intervals of ≥ 1 week after the initial examination, and permanent AF was defined as AF that was present for at least 6 months without intervening spontaneous episodes of sinus rhythm for which cardioversion was unsuccessful and subsequently not attempted (12). When an ECG could not be obtained thrice during the period, the physicians made a clinical judgment regarding the onset time of AF progression. When electrical cardioversion was performed after > 7 days from AF onset, it was also considered as AF progression. We calculated the CHADS2-score (congestive heart failure, hypertension, age [≥ 75 yr], diabetes mellitus, and history of stroke or TIA; 2 points). The CHA2DS2-VASc score was also determined, which also includes vascular disease (previous myocardial infarction, complex aortic plaque, and peripheral artery disease [PAD]), age 65-74 (13, 14). Atrial arrhythmia during follow-up was assumed based on recurrence of any symptoms ECG showing atrial premature complex, atrial tachycardia, or atrial flutter.

Re-admission was defined as any hospitalization of cardiac causes including AF symptoms related admission, embolic events, anticoagulation, others (percutaneous coronary intervention, coronary angiogram, permanent pacemaker insertion, etc.).

Definition of HATCH score
The HATCH score has been proposed as predictive of AF progression in pharmacologically treated AF patients (4). The HATCH acronym stands for hypertension (1 point), age ≥ 75 yr (1 point), transient ischemic attack or stroke (2 points), chronic obstructive pulmonary disease (1 point), and heart failure (2 points).

Transthoracic echocardiography
All enrolled subjects underwent 2-dimensional transthoracic echocardiography (TTE). All examinations were performed using a commercially available Vivid 7TM (GE Medical System, Vingmed, Horten, Norway) ultrasound system. All recorded echocardiograms were measured and interpreted with clinical information blinded using a computerized off-line analysis station (Echopac® 6.3.4; GE Medical System).

All measurements were derived from 3 consecutive cardiac cycles and averaged. The left ventricular (LV) dimensions, wall thicknesses and left atrial dimensions (LAD) were determined in the parasternal long-axis view with the M-mode cursor positioned just beyond the mitral leaflet tips perpendicular to the long axis of the ventricle according to the recommendations of the American Society of Echocardiography (15). The LV ejection fraction (LVEF) was obtained via the modified biplane Simpson method from the apical 4- and 2-chamber views.

Statistical analysis
All continuous variables are expressed as either mean ± standard deviation (SD) or median (25th, 75th interquartile range), depending on the distribution. For continuous data, statistical differences were evaluated using Student’s t-test or the Mann-Whitney U test, depending on the data distribution. Categorical variables are presented as frequencies (percent) and were analyzed using the chi-square test. To determine whether any of the variables were independently related to early recurrence of AF, a multivariate analysis of variables with a P value < 0.05 in the univariate analysis was performed using linear logistic regression analysis. All correlations were calculated using Spearman’s rank correlation test. All statistical analyses were conducted using SPSS statistical software, version 19.0 (SPSS Inc., Chicago, IL, USA), and statistical significance was set at P < 0.05 (two-sided).

Ethics statement
This study protocol was reviewed and approved by the institutional review board of Samsung Medical Center (IRB No. SMC 2014-04-046). Informed consent was waived by the board.

RESULTS
The baseline demographics for both groups are listed in Table 1. This study consisted of 168 subjects with progression to PeAF or permanent AF and 253 subjects without AF progression. Baseline characteristics were not statistically different between the AF progression subjects and the non-AF progression subjects, except for age at diagnosis (P = 0.019), BMI (P = 0.042), and amiodarone medications (P = 0.010). In our study, there was no difference in HATCH scores between the groups (P = 0.537), which is known as a modest predictor of progression to sustained AF (4).

Table 2 shows the laboratory and echocardiographic findings in patients with PAF at baseline. LVEF was lower in the AF pro-
Atrial Fibrillation Progression

DISCUSSION

In this study, we show that the mean annual AF progression rate from PAF to PeAF or permanent AF in Korean populations was 10.7% at 6-yr follow-up and the patients with larger left atrial chamber size and severe MR grade were more likely to experience such progression, suggesting that underlying diseases might cause chronic stretching and atrial dilation, which seem to be important stimuli for chronic atrial structural remodeling. This is consistent with a previous study (16) that found chronic structural changes with cellular hypertrophy, fibroblast proliferation, and tissue fibrosis enables maintenance of AF. Younger patients at diagnosis and the patients with atrial arrhythmia during follow-up were also more likely to have experience progression of PAF to PeAF or permanent AF in our study. Considering the longer duration from the first diagnosis of PAF and in view of the fact that younger patients are associated with higher chances to make more substrates that might be arrhythmogenic foci, the age at diagnosis of PAF might be a good correlate to predict AF progression. And atrial arrhythmia during follow-up might be a clue for the progression of chronic atrial remodeling as arrhythmogenic substrates. Therefore, in these patients, intensive medical therapy with close clinical follow up is required.

This is the first study to evaluate the prognosis of patients with AF progression and validate a risk stratification to assess the probability of AF progression in Korean populations. Various factors were associated with AF progression, including valvular disease, alcohol consumption, age, left atrial dimension and enlargement over time, stroke, and heart failure. In our study, age at diagnosis, atrial arrhythmia during follow-up, LAD and MR grade were associated with AF progression.

Aging is associated with an increase in the prevalence of AF.

Table 2. Baseline laboratory and echocardiographic findings in patients with PAF depending on the progression to persistent or permanent AF

| Parameters | PAF or SR group (n = 253) | Progression to PeAF or permanent AF group (n = 168) | P value |
|------------|---------------------------|-------------------------------------------------|---------|
| Laboratory findings | | | |
| Bilirubin (mg/dL) | 1.0 ± 2.7 | 0.9 ± 0.5 | 0.768 |
| AST (mg/dL) | 27.5 ± 30.1 | 28.8 ± 26.7 | 0.639 |
| ALT (mg/dL) | 27.1 ± 23.8 | 26.4 ± 16.4 | 0.697 |
| Glucose (mg/dL) | 114.8 ± 39.6 | 117.4 ± 53.6 | 0.605 |
| Total cholesterol (mg/dL) | 178.0 ± 38.6 | 181.5 ± 35.9 | 0.375 |
| LDL (mg/dL) | 109.8 ± 30.5 | 114.6 ± 29.8 | 0.213 |
| HDL (mg/dL) | 52.0 ± 16.0 | 50.3 ± 11.9 | 0.371 |
| Triglyceride (mg/dL) | 135.7 ± 99.2 | 123.1 ± 58.3 | 0.231 |
| Creatinine (mg/dL) | 1.0 ± 0.5 | 1.1 ± 0.7 | 0.184 |
| CRP (mg/dL) | 1.9 ± 3.0 | 1.3 ± 0.4 | 0.613 |
| BNP (pg/mL) | 190.1 ± 237.5 | 195.9 ± 145.1 | 0.967 |
| TSH (µIU/mL) | 3.5 ± 12.4 | 2.4 ± 1.7 | 0.413 |
| fT4 (µg/dL) | 1.3 ± 0.5 | 1.3 ± 0.3 | 0.870 |
| Echo parameters | | | |
| LVEF (%) | 62.9 ± 9.0 | 59.9 ± 8.9 | 0.001 |
| LVDDs (mm) | 30.1 ± 4.9 | 31.8 ± 4.8 | 0.001 |
| LVIDd (mm) | 49.5 ± 4.5 | 50.1 ± 4.8 | 0.191 |
| Concentric LVH | 44 (18.0) | 49 (29.5) | 0.008 |
| IVSD (mm) | 9.1 ± 1.5 | 9.6 ± 2.2 | 0.005 |
| LVPWD (mm) | 8.9 ± 1.4 | 9.5 ± 2.8 | 0.002 |
| LAD (mm) | 40.4 ± 6.1 | 43.5 ± 6.8 | < 0.001 |
| LAD ≥ 50 mm | 17 (7.0) | 31 (18.8) | < 0.001 |
| LAVI (mL/m²) | 34.3 ± 13.0 | 39.8 ± 14.2 | 0.004 |
| E velocity (cm/sec) | 0.7 ± 0.3 | 0.7 ± 0.2 | 0.631 |
| A velocity (cm/sec) | 0.7 ± 0.2 | 3.2 ± 2.0 | 0.142 |
| E/A | 1.0 ± 0.4 | 1.3 ± 1.2 | 0.004 |
| E' | 0.1 ± 0.2 | 0.1 ± 0.3 | 0.068 |
| A' | 0.2 ± 1.5 | 0.1 ± 0.02 | 0.620 |
| E/E' | 10.2 ± 4.9 | 9.3 ± 3.4 | 0.204 |
| MR grade | 1.1 ± 0.3 | 1.2 ± 0.5 | < 0.001 |
| TR grade | 1.2 ± 0.4 | 1.2 ± 0.4 | 0.309 |

Values are mean ± SD (range), PAF indicates paroxysmal atrial fibrillation; SR, sinus rhythm; PeAF, persistent atrial fibrillation; AF, atrial fibrillation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LVEF, left ventricular ejection fraction; LVDDs, left ventricular diastolic diameter; LVIDd, left ventricular systolic diameter; LVH, left ventricular hypertrophy; IVSD, interventricular septal diameter; LVPWD, left ventricular posterior wall diameter; LAD, left atrial diameter; LAVI, left atrial volume index; E, peak mitral flow velocity of the early rapid filling wave; A, peak velocity of the late filling wave due to atrial contraction; E', early diastolic mitral annular velocity; A', late diastolic mitral annular velocity; MR, mitral regurgitation; TR, tricuspid regurgitation.

progression subjects compared with the non-AF progression subjects (P < 0.001). Left atrial chamber size (LAD, P < 0.001; LAD ≥ 50 mm, P < 0.001; left atrial volume index [LAVI], P = 0.004), concentric left ventricular hypertrophy (LVH, P = 0.008), and mitral regurgitation (MR) grade (P < 0.001) were higher in AF progression subjects compared with non-AF progression subjects as determined by TTE.

The clinical outcomes in patients with PAF at the 6-yr follow-up are shown in Table 3. The incidences of any event (P < 0.001), re-admission rate (P = 0.001), arrhythmic events (P = 0.021) and DC cardioversion rate for rhythm control (P < 0.001) were higher in AF progression subjects compared with non-AF progression subjects.

In univariate analysis, age at diagnosis, BMI, atrial arrhythmia during follow-up, LVEF, concentric LVH, LAD, and MR grade were significantly associated with AF progression. In multivariate analysis, age at diagnosis (P = 0.009), atrial arrhythmia during follow-up (P = 0.015), LAD (P = 0.002) and MR grade (P = 0.026) were independent risk factors for AF progression from PAF to PeAF or permanent AF (Table 4) at the long-term follow-up.

Kaplan-Meier curves show that the event free survivals of total mortality, thromboembolic events, arrhythmic events and hospitalizations (P < 0.001; Fig. 2) and event free survivals of arrhythmic events (P = 0.002; Fig. 3) are lower in AF progression subjects compared with non-AF progression subjects at the 6-yr follow-up. Fig. 4 shows that mean annual AF progression rate from PAF to PeAF or permanent AF in Korean populations was 10.7% at the 6-yr follow-up.
The fibrosis in promoting the perpetuation of AF in aging hearts and age related development of collagenous septa have been described in human histological studies (4, 10, 17). In our study, patients with AF progression also were older than those without AF progression. This relationship between aging and atrial fibrosis is probably the major explanation of progression to permanent AF.

It is of interest that the patients with AF progression were younger at diagnosis, suggesting that AF duration was longer in the AF progression group. This finding is consistent with previous reports that as PAF lasted longer, progression to PeAF became more likely, which led to the adoption of the now oft-quoted adage "AF begets AF" (18-20).

In our study, LAD and MR grade were independent risk fac-

Table 3. Clinical outcomes in patients with PAF at 6-year follow-up

| Outcomes                        | PAF or SR group (n = 253) | Progression to PeAF or permanent AF group (n = 168) | P value |
|---------------------------------|---------------------------|-----------------------------------------------------|---------|
| Follow-up duration (months)     | 76.8 ± 60.0               | 66.4 ± 55.3                                         | 0.076   |
| Total patients, (%) : follow-up duration > 6 yr | 82 (32.4)                | 56 (33.3)                                           | 0.916   |
| Total any events (%)            | 123 (48.6)                | 119 (70.8)                                          | < 0.001 |
| Re-admission (%)                | 85 (33.6)                 | 85 (50.6)                                           | 0.001   |
| Causes of admission             |                           |                                                    |         |
| AF symptoms related admission (%) | 67 (26.5)                | 66 (39.3)                                           |         |
| Embolic events (%)              | 1 (0.4)                   | 3 (1.8)                                             |         |
| Anticoagulation (%)             | 2 (0.8)                   | 3 (1.8)                                             |         |
| Others (PCI, CAG, PPM etc., %)  | 15 (5.9)                  | 13 (7.7)                                            |         |
| Total death (%)                 | 3 (1.2)                   | 1 (0.6)                                             | 1.000   |
| Cardiac death (%)               | 2 (0.8)                   | 1 (0.6)                                             |         |
| Non-cardiac death (%)           | 1 (0.4)                   | 0 (0)                                               |         |
| Total thromboembolic events (%) | 6 (2.4)                   | 6 (3.6)                                             | 0.436   |
| CVA (new onset, %)              | 5 (2.0)                   | 6 (3.6)                                             |         |
| Peripheral thromboembolism (%)  | 1 (0.4)                   | 0 (0)                                               |         |
| Bleeding complications (%)      | 26 (10.3)                 | 18 (10.7)                                           | 0.872   |
| Arrhythmic events (%)           | 15 (5.9)                  | 21 (12.5)                                           | 0.021   |
| APC or AfAch (%)                | 8 (3.2)                   | 8 (4.8)                                             |         |
| Atrial flutter (%)              | 4 (1.6)                   | 7 (4.2)                                             |         |
| VPC (%)                         | 0 (0)                     | 2 (1.2)                                             |         |
| AV block (%)                    | 3 (1.2)                   | 4 (2.4)                                             |         |
| Treatment of AF                 |                           |                                                    |         |
| DC cardioversion for rhythm control (%) | 10 (4.0)             | 33 (19.6)                                           | < 0.001 |
| RFCA (%)                        | 10 (4.0)                  | 14 (8.3)                                            | 0.084   |
| Follow-up echo parameters; No (%) | 156 (61.7)               | 128 (76.2)                                          | 0.002   |
| LVEF (%)                        | 61.7 ± 9.6                | 60.1 ± 10.1                                         | 0.181   |
| LVIDs (mm)                      | 30.4 ± 5.5                | 31.4 ± 5.1                                          | 0.319   |
| LVIDd (mm)                      | 50.5 ± 5.0                | 50.1 ± 4.6                                          | 0.595   |
| Concentric LVH (%)              | 18 (11.5)                 | 22 (14.7)                                           | 0.230   |
| IVSD (mm)                       | 9.0 ± 1.2                 | 9.1 ± 1.5                                           | 0.759   |
| LVPWD (mm)                      | 8.8 ± 1.2                 | 8.9 ± 1.2                                           | 0.343   |
| LAD (mm)                        | 43.1 ± 7.8                | 47.6 ± 8.1                                          | < 0.001 |
| LAVI (mL/m²)                    | 48.2 ± 30.9               | 58.1 ± 31.3                                         | 0.010   |
| E velocity (cm/sec)             | 0.7 ± 0.3                 | 0.9 ± 0.3                                           | 0.001   |
| A velocity (cm/sec)             | 0.8 ± 0.2                 | 0.6 ± 0.4                                           | 0.012   |
| E/A                             | 0.9 ± 0.5                 | 1.7 ± 1.2                                           | < 0.001 |
| E'                              | 0.1 ± 0.1                 | 0.1 ± 0.8                                           | 0.142   |
| A'                              | 0.1 ± 0.1                 | 0.1 ± 0.02                                          | 0.202   |
| E/E'                            | 11.2 ± 6.1                | 11.3 ± 6.2                                          | 0.910   |
| MR grade                        | 1.2 ± 0.5                 | 1.4 ± 0.6                                           | 0.019   |
| Moderate or severe MR           | 28 (17.9)                 | 36 (28.1)                                           | 0.046   |
| TR grade                        | 1.3 ± 0.6                 | 1.5 ± 1.7                                           | 0.001   |
| Moderate or severe TR           | 33 (21.2)                 | 52 (40.6)                                           | < 0.001 |

Values are mean ± SD (range). PAF indicates paroxysmal atrial fibrillation; SR, sinus rhythm; PeAF, persistent atrial fibrillation; AF, atrial fibrillation; PCI, percutaneous coronary intervention; CAG, coronary angiography; PPM, pacemaker insertion; CVA, cerebrovascular accidents; APC, atrial premature complex; AFacho, atrial tachycardia; VPC, ventricular premature complex; RFCA, radiofrequency catheter ablation; LVEF, left ventricular ejection fraction; LVIDd, left ventricular diastolic diameter; LVIDs, left ventricular systolic diameter; LVH, left ventricular hypertrophy; IVSD, interventricular septal diameter; LVPWD, left ventricular posterior wall diameter; LAD, left atrial diameter; LAVI, left atrial volume index; E, peak mitral flow velocity of the early rapid filling wave; A, peak velocity of the late filling wave due to atrial contraction; E'; early diastolic mitral annular velocity; A', late diastolic mitral annular velocity; MR, mitral regurgitation; TR, tricuspid regurgitation.
Table 4. Univariate and multivariate Cox analyses for progression from paroxysmal atrial fibrillation to persistent or permanent atrial fibrillation at 6-year follow-up

| Variables        | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | P value |
|------------------|-------------|---------|-------------|---------|-------------|---------|-------------|---------|
| Age at diagnosis | 0.979 (0.961-0.997) | 0.020 | 0.973 (0.954-0.993) | 0.009 | 1.000 (0.966-1.035) | 0.994 | 0.973 (0.954-0.993) | 0.009 |
| BMI              | 1.071 (1.002-1.145) | 0.043 | 0.978 (0.877-1.091) | 0.691 | 0.973 (0.954-0.993) | 0.009 | 0.978 (0.877-1.091) | 0.691 |
| Atrial arrhythmia* | 2.258 (1.330-3.834) | 0.003 | 2.022 (1.149-3.557) | 0.015 | 3.040 (1.498-6.171) | 0.002 | 2.022 (1.149-3.557) | 0.015 |
| LVEF             | 0.962 (0.941-0.985) | 0.001 | 0.988 (0.952-1.025) | 0.525 | 0.962 (0.941-0.985) | 0.001 | 0.988 (0.952-1.025) | 0.525 |
| Concentric LVH   | 1.913 (1.200-3.050) | 0.006 | 1.350 (0.504-3.617) | 0.551 | 1.913 (1.200-3.050) | 0.006 | 1.350 (0.504-3.617) | 0.551 |
| LAD              | 1.079 (1.044-1.116) | < 0.001 | 1.058 (1.020-1.098) | 0.002 | 1.067 (1.011-1.126) | 0.019 | 1.058 (1.020-1.098) | 0.002 |
| LAD ≥ 50 mm      | 3.076 (1.640-5.768) | < 0.001 | 3.042 (1.051-8.803) | 0.040 | 3.042 (1.051-8.803) | 0.040 | 3.042 (1.051-8.803) | 0.040 |
| MR grade         | 2.394 (1.450-3.952) | 0.001 | 1.93 (1.079-3.324) | 0.026 | 2.114 (0.635-7.041) | 0.223 | 1.93 (1.079-3.324) | 0.026 |

*Atrial arrhythmia indicates atrial arrhythmia during follow-up including atrial premature complex, atrial tachycardia and atrial flutter. OR, odds ratio; CI, confidence interval; BMI, body mass index; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LAD, left atrial diameter; MR, mitral regurgitation.

Fig. 2. Kaplan-Meier analysis for event free survival from total mortality, thromboembolic events, arrhythmic events and hospitalizations in both study groups.

Fig. 3. Kaplan-Meier analysis for event free survival from arrhythmic events in both study groups.

Fig. 4. Progression rates from PAF to PeAF or permanent AF. *Mean annual progression rate for 6 yr-10.7%/yr.

Factors for predicting AF progression at long-term follow-up. The Framingham Heart Study demonstrated a 42% increased risk for development of AF with every 5 mm increment in left atrial size and the CARAF study demonstrates an increased risk of progressing to permanent AF with LADs in the upper range of normal or minimally enlarged (40-45 mm), a risk that increases further with larger diameters (9, 21). In our study, LAD (< 0.001) and larger LAD ≥ 50 mm (P < 0.001) also were associated with AF progression in univariate analysis and LAD in logistic analysis (OR 1.071 [1.002-1.145], P = 0.044) was an independent risk factor for prediction of AF progression in multivariate analysis.

Mitrail regurgitation grade was associated with an increased probability of AF progression in our study. This finding is consistent with previous studies (9, 22) that have found that valvular lesions, such as moderate to severe mitral regurgitation and aortic stenosis, increase left atrial pressure and stretching and
increase the propensity of AF.

There are higher incidences of total any events, including readmission, arrhythmic events and DC cardioversion rate for rhythm control in patients with AF progression to PeAF or permanent AF at 6-yr follow-up, which supports the need to predict AF progression.

Previous studies have shown that a considerable number of patients with AF also develop clinically relevant sinus node dysfunction and AV block requiring permanent pacemakers (23, 24). In our study, there was a higher incidence of AV block in patients with AF progression (Table 3), which likely reflects an underlying atrial remodeling progression that may be involved as a substrate of AF both functionally and anatomically.

Arrhythmic events including atrial premature complex, atrial tachycardia (AT) and atrial flutter were also higher in patients with AF progression. This finding is consistent with a previous study (25) that found that patients destined to convert to PeAF were more likely to have AT/AF on any particular day and had a higher mean and median AT/AF burden that also increased progressively with time.

In our study, BMI was higher in patients with AF progression. This finding is consistent with the previous studies that showed the relationship among electromechanical remodeling and metabolic syndrome and that obesity and overweight are risk factors for incident AF (26, 27).

The rate of AF progression described in past studies varied between 8% and 22% after 1 yr of follow-up, depending on the rhythm monitoring methods used and definitions (9, 28). In our study, the mean annual AF progression rate was 10.6% (Fig. 4).

Based on the predictors of AF progression, a risk stratification rule to estimate the probability of AF progression in patients with PAF, the HATCH score, was developed (4, 29, 30). The premise of the HATCH score is early selection of patients for rhythm control therapy in an effort to prevent disease progression (4). However, in our study, there was no difference in HATCH score between groups.

Our study is the first to demonstrate a younger age at diagnosis-consistent with longer duration of AF, atrial arrhythmia during follow-up, left atrial chamber size, severe MR grade-important factors of electrical and structural remodeling. Those factors are associated with AF progression from PAF to PeAF or permanent AF in Korean populations.

There are some limitations to our study. First, this study was a single-center, retrospective study derived from a real world practice with inherent limitations. Hence the results of our study should be considered as hypothesis generating, and future prospective studies are warranted to confirm our results. Second, the definition of AF progression that we selected is arbitrary. In clinical practice, it is extremely difficult to determine the progression from PeAF to permanent AF because of the lack of a firm end point. Therefore, we defined AF progression to be from PAF to PeAF or permanent AF. Third, using the CARAF definitions, non-differential misclassification of PeAF and permanent AF is possible. To adjust for this, we required 2 consecutive annual visits with ECG evidence of permanent AF before the patient was designated as permanent for the analysis, making it likely that most patients with permanent AF would fit the newer definition (9, 31, 32). Fourth, patients with potentially reversible causes were excluded from the study. Therefore, the results of this study cannot be transferred to other patient populations with first detected PAF. Finally, according to current guidelines, catheter ablation was performed only in the few patients who had drug-refractory AF or who were intolerant to antiarrhythmic drug therapy.

In conclusion, the patients with younger age at diagnosis, atrial arrhythmia during follow-up, larger left atrial chamber size and severe MR grade are more likely to progress to PeAF or permanent AF, suggesting more intensive medical therapy with close clinical follow up would be required in those patients.

**DISCLOSURE**

The authors declared no potential conflicts of interest.

**AUTHOR CONTRIBUTION**

Conception and coordination of the study: On YK, Im SI. Design of ethical issues: Park KM, On YK, Kim JS. Acquisition of data: Im SI, On YK. Data review: Im SI, On YK. Statistical analysis: Im SI, Park SJ, Huh J, On YK. Manuscript preparation: Im SI, On YK. Manuscript approval: all authors

**ORCID**

Sung II Im http://orcid.org/0000-0003-2544-2422  
Young Keun On http://orcid.org/0000-0003-1025-7283

**REFERENCES**

1. Jahangir A, Murarka S. Progression of paroxysmal to persistent atrial fibrillation factors promoting the HATCH score. J Am Coll Cardiol 2010; 55: 732-4.
2. Senoo K, Suzuki S, Otsuka T, Sagara K, Matsuno S, Kano H, Uejima T, Oikawa Y, Yajima J, Nagashima K, et al. Progression to the persistent form in asymptomatic paroxysmal atrial fibrillation. Circ J 2014; 78: 1121-6.
3. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-e176.
4. de Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coenen RJ.
van den Heijlkant AC, Allessie MA, Crijns HJ. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55: 725-31.

5. Kato T, Yamashita T, Sagara K, Inuma H, Fu LT. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Circ J 2004; 68: 568-72.

6. Fujiki A. Progression of atrial fibrillation from paroxysmal to persistent. Circ J 2014; 78: 1058-60.

7. Wyse DG, Gersh BJ. Atrial fibrillation: a perspective: thinking inside and outside the box. Circulation 2004; 109: 3089-95.

8. Chiang CE, Naditch-Brulé L, Murin J, Goethals M, Inoue H, O’Neill J, Silva-Cardoso J, Zharinov O, Gamra H, Alam S, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012; 5: 632-9.

9. Kerr CR, Humphries KH, Talajic M, Klein GJ, Connolly SJ, Green M, Boone J, Sheldon R, Dorian P, Newman D. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J 2005; 149: 489-96.

10. Nieuwlaat R, Prins MH, Le Heuzey JY, Vardas PE, Aliot E, Santini M, Cobbe SM, Widder shoven JW, Baur LH, Lévy S, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29: 1181-9.

11. Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC, Lip GY. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study. Chest 2012; 141: 339-47.

12. Pappone C, Radi novic A, Mangano F, Vicedomini G, Ciconte G, Sacchi S, Mazzone P, Paglini G, Gulletta S, Sala S, et al. Atrial fibrillation progression and management: a 5-year prospective follow-up study. Heart Rhythm 2008; 5: 1501-7.

13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-70.

14. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-72.

15. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanevise J, et al.; Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echo cardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.

16. Andalib A, Brugada R, Nattel S. Atrial fibrillation: evidence for genetically determined disease. Curr Opin Cardiol 2008; 23: 176-83.

17. Kubota T, Kawasaki M, Takasugi N, Imai H, Ishihara Y, Okubo M, Takehashi S, Sato H, Nishigaki K, Takemura G, et al. Left atrial pathological degeneration assessed by integrated backscatter transesophageal echocardiography as a predictor of progression to persistent atrial fibrillation: results from a prospective study of three-years follow-up. Cardiovasc Ultrasound 2012; 10: 28.

18. Lu Z, Scherlag BJ, Lin J, Niu G, Fung KM, Zhao L, Ghias M, Jackman WM, Lazzara R, Jiang H, et al. Atrial fibrillation begets atrial fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. Circ Arrhythm Electrophysiol 2008; 1: 184-92.

19. Rostock T, Steven D, Lutomsny B, Servatius H, Drewitz I, Klemm H, Müllerleile K, Ventura R, Meintertz T, Willems S. Atrial fibrillation begets atrial fibrillation in the pulmonary veins on the impact of atrial fibrillation on the electrophysiological properties of the pulmonary veins in humans. J Am Coll Cardiol 2008; 51: 2153-60.

20. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.

21. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271: 840-4.

22. DE Sisti A, Leclercq JF, Halimi F, Fiorello P, Bertrand C, Attuel P. Evaluation of time course and predicting factors of progression of paroxysmal or persistent atrial fibrillation to permanent atrial fibrillation. Pacing Clin Electrophysiol 2014; 37: 345-55.

23. Gomes IA, Kang PS, Matheson M, Gough WB Jr, El-Sherif N. Coexistence of sick sinus rhythm and atrial flutter-fibrillation. Circulation 1981; 63: 80-6.

24. van den Berg MP, van Gelder IC. Atrial fibrillation and sinus node dysfunction. J Am Coll Cardiol 2001; 38: 1585-6.

25. Homoud MK, Estes M 3rd. Shedding new light on the pathophysiology of conversion of paroxysmal atrial fibrillation into persistent atrial fibrillation. Am Heart J 2007; 154: 801-4.

26. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2014; 7: 620-5.

27. Hung CL, Chao TF, Lai YH, Wen CH, Wang KL, Tsao HM, Lin YJ, Chang SL, Lo LW, Hu YF, et al. The relationship among atrium electromechanical interval, insulin resistance, and metabolic syndrome. Can J Cardiol 2013; 29: 1263-8.

28. Gianfranchi L, Brignole M, Menozzi C, Lolli G, Bottoni N. Determinants of development of permanent atrial fibrillation and its treatment. Europace 1999; 1: 35-9.

29. Barrett TW, Selb WH, Wasserman BS, McNaulton CD, Darobar D. Evaluating the HATCH score for predicting progression to sustained atrial fibrillation in ED patients with new atrial fibrillation. Am J Emerg Med 2013; 31: 792-7.

30. Schmidt EU, Schneider R, Lauschke J, Wendig I, Bänsch D. Atrial fibrillation begets atrial fibrillation: autonomic mechanism for atrial electrical remodeling induced by short-term rapid atrial pacing. Circ Arrhythm Electrophysiol 2008; 1: 184-92.

31. Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ, Kerr CR, Gent M, Thoepe KE, Roberts RS, Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001; 38: 167-72.

32. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2014; 7: 620-5.

33. Skanes AC, Krahn AD, Yee R, Klein GJ, Connolly SJ, Kerr CR, Gent M, Thorpe KE, Roberts RS, Canadian Trial of Physiologic Pacing. Progression to chronic atrial fibrillation after pacing: the Canadian Trial of Physiologic Pacing. CTOPP Investigators. J Am Coll Cardiol 2001; 38: 167-72.

34. Humphries KH, Kerr CR, Connolly SJ, Klein G, Boone JA, Green M, Sheldon R, Talajic M, Dorian P, Newman D. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001; 103: 2365-70.